Michael Bennet (D-CO)

Prescription Drug Supply Chain Pricing Transparency Act

S. 3751 · Senate bill Health

A Democratic bill with 1 Republican cosponsor · See the cosponsor

Last activity — Read twice and referred to the Committee on Finance.

In committee

Introduced and handed to a committee in the chamber it started in.

The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.

Its path through Congress

  1. Introduced
  2. In Committee

What this bill would do

This bill, titled the "Prescription Drug Supply Chain Pricing Transparency Act," directs the Comptroller General of the United States to perform a specific study. The study focuses on compensation and payment structures tied to prescription drug prices within the retail supply chain. It aims to examine how various intermediaries, such as pharmacy benefit managers and drug wholesalers, are compensated. The Comptroller General is tasked with looking at business models, potential conflicts of interest, and pricing trends. Finally, a report including recommendations for legislation or administrative action must be submitted to Congress within two years.

Yes· 3 of 8

  • Scored +4

    Does this make what the government does easier for the public to see?

    The bill increases transparency by requiring a formal study and report on the compensation structures within the prescription drug supply chain.

  • Scored +3

    Does this lower the price of prescription medicines?

    The study seeks to understand and provide recommendations to address compensation structures that may drive up drug prices.

  • Scored +3

    Does this give people more protection from unfair business practices?

    The study aims to identify conflicts of interest where compensation structures might favor higher-priced drugs, which could protect consumers from inflated costs.

The opposite

  • Scored -2

    Would business owners be better off under this?

    The study investigates the compensation and business models of drug wholesalers and pharmacy benefit managers.